Prevalence, virology and antiviral drugs susceptibility of hepatitis B virus rtN238H polymerase mutation from 1865 Chinese patients with chronic hepatitis B

Antiviral Research

Volumn 93, Issue 1, 2012, Pages 185-190

  Zhong, Yanwei ^a   Lv, Jiyun ^a   Li, Jin ^a   Xing, Xiaoyan ^a   Zhu, Hua ^a   Su, Heling ^a   Chen, Li ^a   Zhou, Xianzhi ^a  

^a BEIJING 302 HOSPITAL   (China)

Author keywords

Adefovir; Drug resistance; Hepatitis B virus; Lamivudine; Polymorphism

Indexed keywords

ADEFOVIR; ALANINE AMINOTRANSFERASE; AMINO ACID; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; VIRUS DNA;

ADOLESCENT; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMINO ACID SUBSTITUTION; ANTIBODY DETECTION; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CHILD; CHINESE; CHRONIC HEPATITIS; CONTROLLED STUDY; FEMALE; GENE LOCUS; GENE MUTATION; GENETIC POLYMORPHISM; GENOTYPE; HEPATITIS B; HEPATOMA CELL; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IN VITRO STUDY; INFECTION RATE; INFLAMMATION; LIVER CIRRHOSIS; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PREVALENCE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS; SEROLOGY; VIROLOGY; VIRUS LOAD; VIRUS REPLICATION;

ADENINE; ADOLESCENT; ADULT; AGED; AMINO ACID SUBSTITUTION; ANTIVIRAL AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; CHILD; CHILD, PRESCHOOL; CHINA; FEMALE; GENOTYPE; HEP G2 CELLS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MUTATION; MUTATION RATE; PHOSPHONIC ACIDS; RNA-DIRECTED DNA POLYMERASE; VIRUS REPLICATION; YOUNG ADULT;

HEPATITIS B VIRUS;

EID: 84355162290     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2011.11.012     Document Type: Article

References (26)

1. Akman S.A., Kose S., Halicioglu O. Lamivudine and adefovir resistance in children and young adults with chronic hepatitis B. Int. J. Infect. Dis. 2010, 14:e236-239.
2. Angus P., Vaughan R., Xiong S., Yang H., Delaney W.E., Gibbs C., Brosgart C., Colledge D., Edwards R., Ayres A., Bartholomeusz A., Locarnini S. Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology 2003, 125:292-297.
3. Bartholomeusz A., Locarnini S.A. Antiviral drug resistance. clinical consequences and molecular aspects. Semin. Liver. Dis. 2006, 26:162-170.
4. Borroto-Esoda K., Miller M.D., Arterburn S. Pooled analysis of amino acid changes in the HBV polymerase in patients from four major adefovir dipivoxil clinical trials. J. Hepatol. 2007, 47:492-498.
5. Brunelle M.N., Jacquard A.C., Pichoud C., Durantel D., Carrouée Durantel S., Villeneuve J.P., Trépo C., Zoulim F. Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir. Hepatology 2005, 41:1391-1398.
6. Chotiyaputta W., Lok A.S. Hepatitis B virus variants. Nat. Rev. Gastroenterol. Hepatol. 2009, 6:453-462.
7. Durantel D., Carrouée-Durantel S., Werle-Lapostolle B., Brunelle M.N., Pichoud C., Trépo C., Zoulim F. A new strategy for studying in vitro the drug susceptibility of clinical isolates of human hepatitis B virus. Hepatology 2004, 40:855-864.
8. Gallego A., Sheldon J., García-Samaniego J., Margall N., Romero M., Hornillos P., Soriano V., Enriquez J. Evaluation of initial virological response to adefovir and development of adefovir-resistant mutations in patients with chronic hepatitis B. J. Viral Hepat. 2008, 15:392-398.
9. Ghany M., Liang T.J. Drug targets and molecular mechanisms of drug resistance in chronic hepatitis B. Gastroenterology 2007, 132:1574-1585.
10. Kao J.H., Chen P.J., Lai M.Y., Chen D.S. Basal core promoter mutations of hepatitis B virus increase the risk of hepatocellular carcinoma in hepatitis B carriers. Gastroenterology 2003, 124:327-334.
11. Koichiro T., Joel D., Masatoshi N., Sudhir K. MEGA4: Molecular Evolutionary Genetics Analysis (MEGA) Software Version 4.0. Mol Biol Evol 2007, 24:1596-1599.
12. Li X., Wang L., Zhong Y., Wong V.W., Xu Z., Liu Y., Li Q., Xin S., Zhao J., Xu D. Hepatitis B virus (HBV) subgenotypes C2 and B2 differ in lamivudine- and adefovir-resistance-associated mutational patterns in HBV-infected Chinese patients. J. Clin. Microbiol. 2010, 48:4363-4369.
13. Liu Y., Wang C., Zhong Y., Li X., Dai J., Ren X., Xu Z., Li L., Yao Z., Ji D., Wang L., Zhang L., Wong V.W., Zoulim F., Xu D. Genotypic resistance profile of hepatitis B virus (HBV) in a large cohort of nucleos(t)ide analogue-experienced Chinese patients with chronic HBV infection. J. Viral Hepat. 2011, 18:e29-39.
14. Locarnini S., Mason W.S. Cellular and virological mechanisms of HBV drug resistance. J. Hepatol. 2006, 44:422-431.
15. Lok A.S., Zoulim F., Locarnini S., Bartholomeusz A., Ghany M.G., Pawlotsky J.M., Liaw Y.F., Mizokami M., Kuiken C. Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management. Hepatology 2007, 46:254-265.
16. McMahon B.J. The influence of hepatitis B virus genotype and subgenotype on the natural history of chronic hepatitis B. Hepatol. Int. 2009, 3:334-342.
17. Qi X., Xiong S., Yang H., Miller M., Delaney W.E. In vitro susceptibility of adefovir-associated hepatitis B virus polymerase mutations to other antiviral agents. Antivir. Ther. 2007, 12:355-362.
18. Shaw T., Bartholomeusz A., Locarnini S. HBV drug resistance. mechanisms, detection and interpretation. J. Hepatol. 2006, 44:593-606.
19. Sheldon J., Rodès B., Zoulim F., Bartholomeusz A., Soriano V. Mutations affecting the replication capacity of the hepatitis B virus. J. Viral Hepat. 2006, 13:427-434.
20. Sumi H., Yokosuka O., Seki N., Arai M., Imazeki F., Kurihara T., Kanda T., Fukai K., Kato M., Saisho H. Influence of hepatitis B virus genotypes on the progression of chronic type B liver disease. Hepatology 2003, 37:19-26.
21. Tacke F., Manns M.P., Trautwein C. Influence of mutations in the hepatitis B virus genome on virus replication and drug resistance-implications for novel antiviral strategies. Curr. Med. Chem. 2004, 11:2667-2777.
22. Tacke F., Gehrke C., Luedde T., Heim A., Manns M.P., Trautwein C. Basal core promoter and precore mutations in the hepatitis B virus genome enhance replication efficacy of lamivudine-resistant mutants. J. Virol. 2004, 78:8524-8535.
23. Tonetto P.A., Gonçales N.S., Fais V.C., Vigani A.G., Gonçales E.S., Feltrin A., Gonçales F.L. Hepatitis B virus: molecular genotypes and HBeAg serological status among HBV-infected patients in the southeast of Brazil. BMC Infect. Dis. 2009, 9:149.
24. Yim H.J., Hussain M., Liu Y., Wong S.N., Fung S.K., Lok A.S. Evolution of multi-drug resistant hepatitis B virus during sequential therapy. Hepatology 2006, 44:703-712.
25. Yuen M.F., Lau C.S., Lau Y.L., Wong W.M., Cheng C.C., Lai C.L. Mannose binding lectin gene mutations are associated with progression of liver disease in chronic hepatitis B infection. Hepatology 1999, 29:1248-1251.
26. Zhong Y.W., Li J., Song H.B., Duan Z.P., Dong Y., Xing X.Y., Li X.D., Gu M.L., Han Y.K., Zhu S.S., Zhang H.F. Virologic and clinical characteristics of HBV genotypes/subgenotypes in 487 Chinese pediatric patients with CHB. BMC Infect. Dis. 2011, 11:262.